What do systematic reviews say?

Antioxidants (lycopene, curcumin, Oxitard) vs Placebo or no active treatment

The review found no eligible studies for this question.

• Interventions for managing oral submucous fibrosis 2024 · Cochrane All outcomes
  The trials did not measure quality of life.
  0 studies
  No studies found

Chemotherapy (any regimen; added to, or compared with, locoregional treatment) vs Locoregional treatment and/or an alternative chemotherapy regimen

The review found no eligible studies for this question.

• Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy 2021 · Cochrane All outcomes
  Quality of life was a planned (protocol) outcome but no included trial provided usable quality-of-life data; the protocol was modified to report only survival/response outcomes.
  0 studies
  No studies found

Mechanical tongue cleaning (tongue scraper) vs No tongue cleaning

The review found no eligible studies for this question.

• Interventions for managing halitosis 2019 · Cochrane All outcomes
  Quality of life was a prespecified secondary outcome. None of the 44 included studies in the review (across all comparisons) reported quality-of-life data (review-wide evidence gap).
  0 studies
  No studies found

Amifostine vs no treatment/placebo

Amifostine showed no clear difference in quality of life compared with no treatment/placebo; GRADE not reported.

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes

  End of RT; up to 3 months postRT
  MD 0.52 [-0.02, 1.06]
  1 study · 233 participants
  GRADE not reported

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

The review found no eligible studies for this question.

• Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
  No studies reported this outcome (planned secondary outcome not measured by any study in the review)
  0 studies
  No studies found

Antiseptic mouthrinse vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  No quality of life data were reported.
  0 studies
  No studies found

Bethanechol vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  No data on either quality of life or other oral related symptoms were reported.
  0 studies
  No studies found

Chinese medicine vs no treatment/placebo

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes

  End of intervention to 3 months postRT
  Insufficient evidence to determine any effect on quality of life (Lin 2014; Analysis 6.5)
  1 study
  GRADE not reported

Amifostine (intravenous) vs Amifostine (subcutaneous)

The review found no eligible studies for this question.

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  No data on either quality of life or other oral related symptoms were reported.
  0 studies
  No studies found

Venalot Depot (coumarin plus troxerutin) vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  No data on either quality of life or other oral related symptoms were reported.
  0 studies
  No studies found

Amifostine 200 mg/m2 three times weekly vs Amifostine 200 mg/m2 five times weekly

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes

  End of RT and 6, 12, 18, 24 months postRT
  No significant differences between the three treatment arms (Jellema 2006)
  1 study
  GRADE not reported

Bethanechol vs Artificial saliva

The review found no eligible studies for this question.

• Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes
  No data on either quality of life or other oral related symptoms were reported.
  0 studies
  No studies found

Oral cryotherapy (ice chips, ice-cold water, ice cubes or crushed ice held in the mouth during cancer treatment) vs no intervention or control intervention (control)

• Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy 2015 · Cochrane All outcomes

  High-dose melphalan-based treatment prior to HSCT (haematological cancers)
  Summary of findings 2 (melphalan/HSCT): Quality of life - '1 study assessed this outcome but the data are currently unavailable as the study report and analysis have not yet been completed' (Toro 2013; measured with…
  1 study
  GRADE not reported
• Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy 2015 · Cochrane All outcomes

  Fluorouracil (5FU) treatment for solid cancers
  Summary of findings for the main comparison (5FU solid cancers): Quality of life - 'No studies assessed this outcome'.
  0 studies
  No studies found

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months
  Only one study (Bonner 2006, 424 participants) comprehensively assessed quality of life using EORTC QLQ-C30 (v3.0) and QLQ-H&N35; no statistically significant difference between groups for global health status or any…
  1 study · 424 participants
  GRADE not reported

Electrostimulation (device) vs Placebo (sham/placebo device)

The review found no eligible studies for this question.

• Interventions for the management of dry mouth: non‐pharmacological interventions 2013 · Cochrane All outcomes
  no estimate extracted
  0 studies
  No studies found

Visual screening (oral visual inspection) by trained health workers vs No screening

The review found no eligible studies for this question.

• Screening programmes for the early detection and prevention of oral cancer 2013 · Cochrane All outcomes

  15-year follow-up
  Data on quality of life were not reported.
  0 studies
  No studies found

Acupuncture vs sham

The review found no eligible studies for this question.

• Interventions for the management of dry mouth: non‐pharmacological interventions 2013 · Cochrane All outcomes
  no estimate extracted
  0 studies
  No studies found

Bee propolis (one 500 mg capsule per day) vs placebo

• Systemic interventions for recurrent aphthous stomatitis (mouth ulcers) 2012 · Cochrane All outcomes

  6 months (minimum)
  Patients in the propolis group self-reported a significant improvement in their quality of life (P=0.03), based on volunteered statements of self-reported improvement.
  1 study · 19 participants
  GRADE not reported

Phenytoin mouthrinse vs placebo

Phenytoin mouthrinse led to lower quality of life compared with placebo; GRADE not reported.

• Interventions for treating oral mucositis for patients with cancer receiving treatment 2010 · Cochrane All outcomes

  7 days
  MD -15.10 [-26.04, -4.16]
  1 study · 12 participants
  GRADE not reported

Radiotherapy (morning) vs Afternoon radiotherapy

• Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy 2010 · Cochrane All outcomes
  Bjarnason 2009: no statistically significant difference in quality of life scores (data not reported). Morning radiotherapy was associated with significantly less weight loss after 5 months.
  1 study · 216 participants
  GRADE not reported